Barbra Pagarigan
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Enzyme Structure and Function
Most-Cited Works
- → A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase(2016)641 cited
- → Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs(2014)504 cited
- → A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos(2017)287 cited
- → Structural analysis of a set of proteins resulting from a bacterial genomics project(2005)246 cited
- → Crystal structure of the SALL4–pomalidomide–cereblon–DDB1 complex(2020)98 cited
- → The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen(2017)59 cited
- → Structure of the human marker of self 5-transmembrane receptor CD47(2021)48 cited
- → The 1.59 Å resolution crystal structure of TM0096, a flavin mononucleotide binding protein from Thermotoga maritima(2004)19 cited
- → Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy(2019)17 cited
- → Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes(2014)14 cited